Abstract：Objective To investigate the efficacy of irinotecan combined with cisplatin in the treatment of patientswith cervical cancer and its effect on serum Bcl-2.M ethods 124 cases of cervical cancer patients in our hospital from January 2015 to January 2016 were randomly divided into observation group（62 cases）and control group（62 cases），the observation group were treated with irinotecan combined with cisplatin，the control group were treated with paclitaxel，the curative effect in two groups and its effect on serum Bcl-2 were compared.Results The total effective rate in the observation group was 80.65%，significantly higher than 25.81%in the control group，the difference was statistically significant（P＜0.05）；The Bcl-2 protein expression levels after treatment in the two groupswas significantly lower than that before treatment，and the expression level of Bcl-2 in the observation group after treatmentwas significantly lower than that in the control group，the difference was statistically significant （P＜0.05）.Conclusion The treatment of irinotecan combined with cisplatin in patients with cervical cancer is helpful to decrease the serum level of Bcl-2 and has a significanteffect.which can be popularized in clinic.
杨春霞. 伊立替康联合顺铂治疗宫颈癌患者疗效及对血清Bcl-2的影响研究[J]. 中国当代医药, 2016, 23(20): 75-77.
YANGChun-xia. Research on the curative effect of irinotecan combined w ith cisp latin in treatment of patientsw ith cervical cancer and its effect on serum Bcl-2. 中国当代医药, 2016, 23(20): 75-77.
Lara PN Jr，Chansky K，Shibata T，et al.Common arm comparative outcomes analysis of phase 3 trials of cisplatin+ irinotecan versus cisplatin+etoposide in extensive stage small cell lung cancer：Final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124［J］.Cancer，2010，116（24）：5710-5715.
京公网安备 11010502046607号